Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic
Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month
Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month
Explore the latest science and technology advancements in regenerative medicine, COVID-19 diagnostic testing, cardiovascular treatments, point-of-care and more
Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing
The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction
The availability of an International Standard (IS) for antibodies facilitates the standardization of SARS-CoV-2 serological methods
Platform poised to be first CLIA-waived CRISPR-based, point-of-care COVID-19 device with central-lab performance, developed in collaboration with Sherlock Biosciences
Explore topics from live-cell analysis, in situ hybridization, cancer therapeutics, cell imaging, and much more
For a chance to win a $500/£400/450€ Amazon Gift Card, cast your vote for the new products which have made the most difference to clinical diagnostics
FDA Breakthrough Device Designation for Sepsis, Joint & Implant Infections, Infective Endocarditis, Bacterial Meningitis
In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years
Vaccine, trialed in 450 children, shows favorable safety profile and was well-tolerated
COVID-19 infections fell by 65% percent after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study
A new Prenetics Innovation Technology Centre will be established for advanced molecular diagnostics
Sensor could be used in discovering new treatments for mental illness, in neuroscience research and to detect drugs of abuse
Anti-cancer drug delivery to target tumor sites now becomes more effective with novel multi-stimuli-responsive drug delivery systems
The test offers 98.0% clinical sensitivity for samples with PCR Ct values up to 31
Each line of ValuPanel Reagents consists of separately delivered probes and primers, which allow assay flexibility and sizes that can help facilitate scale-up
AI could hold the key to more targeted treatment, according to new research